Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1351 to 1365 of 2184 results for guidelines

  1. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

    Medtech innovation briefing
    Published
    10 August 2021

  2. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA903

  3. What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    9 March 2022

  4. What models of service delivery enable intraoperative endoscopic retrograde cholangiopancreatography (ERCP) for bile duct clearance to be delivered within the NHS? What are the costs and benefits of different models of service delivery?

    Any explanatory notes(if applicable) Evidence reviewed for this guideline identified that intraoperative ERCP is both clinically and...

    Research recommendation
    Published
    9 June 2015

  5. Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral methotrexate for adults with early onset RA starting a new DMARD?

    with oral drugs. Research on subcutaneous methotrexate will inform future guideline recommendations. Source guidance details Comes from...

    Research recommendation
    Published
    11 December 2018

  6. Red blood cell transfusion thresholds for patients with chronic cardiovascular  disease:- What is the clinical and cost effectiveness of restrictive compared with liberal red blood cell thresholds and targets for patients with chronic cardiovascular disease?

    thresholds in populations with coronary ischaemia at baseline. In this guideline a level of 80–100 g/litre was used for patients with...

    Research recommendation
    Published
    11 December 2015

  7. Digital technologies for managing non-specific low back pain: early value assessment (HTG712)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.

    HealthTech guidance
    Published
    5 March 2024
    View recommendations

    Sections for HTG712

  8. Does a multidisciplinary team agreed approach to weaning from continuous positive airway pressure improve weaning times and result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    12 November 2021

  9. Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without LTRA:- What is the clinical and cost effectiveness of offering additional maintenance therapy to adults, young people and children with asthma that is uncontrolled on a moderate dose of ICS plus LABA with or without LTRA?

    favour the addition of a long-acting muscarinic antagonist (LAMA) but the guideline committee did not consider this to be conclusive,...

    Research recommendation
    Published
    18 October 2018

  10. How effective and cost effective are different types of exercise referral scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome. Compare exercise referral schemes that vary by: - setting – for example, home-based, gym-based, community-based or outdoors - intensity and duration – for example, a 12-week scheme involving 1 session a week, or a 6-week scheme involving 4 1-hour sessions per week - the techniques used, for example, some use additional 'supportive' techniques such as 'motivational interviewing' and education sessions - the target group, for example, people who are overweight and obese, people with raised blood pressure or cholesterol levels or those experiencing mild depression, anxiety or stress; or by age, gender, race or socioeconomic status - other scheme characteristics including: design, content and delivery; referral mechanisms; choice of activity; cost and qualifications of instructors; and whether it is commissioned and delivered by an NHS, non-NHS or community-based organisation.

    doing some physical activity, albeit below current UK physical activity guidelines rather than none at all, should be taken into...

    Research recommendation
    Published
    9 June 2015

  11. What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    12 November 2021

  12. Approaches for micro, small and medium-sized enterprises: What is the long-term effectiveness of universal individual-level interventions in different kinds of SMEs?

    recommendation for research, see the rationale section on making this guideline relevant for small and medium-sized enterprises...

    Research recommendation
    Published
    8 April 2022

  13. What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    12 November 2021

  14. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  15. Embryo selection for single embryo transfer:- Further research is needed to improve embryo selection to facilitate single embryo transfers.

    embryo in order to maximise the chance of pregnancy. As detailed in the guideline, this practice has inherent risks, especially of...

    Research recommendation
    Published
    9 June 2015